Alexandria Real Estate: The Uncertainty Is Real, But The Discount Has Gone Too Far

Alexandria Real Estate Equities, Inc. faces severe leasing headwinds, especially from public biotech tenants, driving market pessimism and a >30% stock decline since mid-2025.

ARE trades at a steep discount—P/FFO ~7x and P/B 0.5x—reflecting deep uncertainty, but its high-quality, irreplicable assets and strong tenant relationships remain valuable.

Balance sheet strength is evident: $28.8B in real estate, $400M cash, and $12.5B debt.

Also, the 2026 FFO guidance is $6.30–$6.50 per share.

Despite ongoing sector challenges and low visibility, I rate ARE stock a Buy, as even a 'less bad' quarter could trigger sentiment recovery given the low expectations.

0%. That’s how much the leasing activity volume of public biotech was in Q1.